Display options
Cite
Chekkal M, Rahal MCA, Moulasserdoun K, et al. Increased Level of Factor VIII and Physiological Inhibitors of Coagulation in Patients with Sickle Cell Disease. Indian J Hematol Blood Transfus. 2016;33(2):235-238doi: 10.1007/s12288-016-0701-z.
Chekkal, M., Rahal, M. C. A., Moulasserdoun, K., & Seghier, F. (2017). Increased Level of Factor VIII and Physiological Inhibitors of Coagulation in Patients with Sickle Cell Disease. Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion, 33(2), 235-238. https://doi.org/10.1007/s12288-016-0701-z
Chekkal, Mohamed, et al. "Increased Level of Factor VIII and Physiological Inhibitors of Coagulation in Patients with Sickle Cell Disease." Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion vol. 33,2 (2017): 235-238. doi: https://doi.org/10.1007/s12288-016-0701-z
Chekkal M, Rahal MCA, Moulasserdoun K, Seghier F. Increased Level of Factor VIII and Physiological Inhibitors of Coagulation in Patients with Sickle Cell Disease. Indian J Hematol Blood Transfus. 2017 Jun;33(2):235-238. doi: 10.1007/s12288-016-0701-z. Epub 2016 Jun 25. PMID: 28596657; PMCID: PMC5442051.
Copy Download .nbib Format: NLM
Share it on

Indian J Hematol Blood Transfus. 2017 Jun;33(2):235-238. doi: 10.1007/s12288-016-0701-z. Epub 2016 Jun 25.

Increased Level of Factor VIII and Physiological Inhibitors of Coagulation in Patients with Sickle Cell Disease.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion

Mohamed Chekkal, Mohamed Chakib Arslane Rahal, Khedidja Moulasserdoun, Fatima Seghier

Affiliations

  1. Medicine Faculty, Department of Hemobiology, Oran University, B.P 15.0 El M'naouer Oran, Algeria.

PMID: 28596657 PMCID: PMC5442051 DOI: 10.1007/s12288-016-0701-z

Abstract

Sickle cell disease (SCD) is a hemoglobinopathy characterized by hemolysis, oxidative stress, and vaso-occlusive crises. Thromboembolism also remains a serious complication and probably underestimated in the SCD. Our objective was to seek the existence of hemostasis abnormalities that predispose to thrombosis such as elevation of FVIII and Physiological inhibitors of coagulation deficiency. We studied 81 patients with SCD, including 32 homozygous S/S, 20 double heterozygous S/β thalassemia and 29 heterozygous S/A. Controls AA were in number 60. For each patient and control we assayed the physiological coagulation inhibitors (Protein C, Protein S and Antithrombin) and the clotting FVIII. We found a significant increase in FVIII in all phenotypes of SCD compared to controls. Also, a significant decrease in levels of protein C and S was observed in patients with sickle cell homozygous or double heterozygous S β Thalassemia compared to controls. As against, for antithrombin no difference was observed between patients and controls. These hemostasis abnormalities therefore reflect the existence of a pro thrombotic state in sickle cell disease that can explain the increase of incidence of thrombosis in this pathology. Factor VIII clotting consistently high in SCD may well be a prime therapeutic target in the treatment of thrombotic manifestations of this disease.

Keywords: Antithrombin; Factor VIII; Protein C; Protein S; Sickle cell disease

References

  1. Lancet. 1999 Apr 3;353(9159):1167-73 - PubMed
  2. Thromb Haemost. 1996 Nov;76(5):651-62 - PubMed
  3. Blood. 2002 Mar 1;99(5):1564-71 - PubMed
  4. Blood. 2003 Oct 1;102(7):2678-83 - PubMed
  5. Hematol Oncol Clin North Am. 2014 Apr;28(2):355-74 - PubMed
  6. Am J Med. 2013 May;126(5):443-9 - PubMed
  7. Hematology Am Soc Hematol Educ Program. 2009;:62-9 - PubMed
  8. Blood. 1991 Apr 1;77(7):1405-14 - PubMed
  9. Semin Hematol. 1997 Jul;34(3):171-87 - PubMed
  10. Lancet. 1995 Jan 21;345(8943):152-5 - PubMed
  11. Pediatr Hematol Oncol. 2003 Sep;20(6):429-34 - PubMed
  12. Blood. 2004 Aug 1;104(3):840-6 - PubMed

Publication Types